This report analyzes the global dental anesthetics market, which is poised for steady growth driven by rising dental procedures, aging populations, and increased oral health awareness. Key highlights include the rapid expansion of the articaine drug type and the topical administration segment, alongside the dominance of dental clinics as primary end users. While challenges like practitioner shortages exist, the Asia Pacific region is expected to lead market growth. The study provides a comprehensive competitive landscape and strategic insights across various segments.

Executive Overview

The global dental anesthetics market is projected to grow from USD 1.48 billion in 2025 to USD 1.80 billion by 2030, representing a compound annual growth rate (CAGR) of 4.0% during the forecast period.

Market Dynamics

Growth Drivers

• Rising Incidence of Dental Issues: An increase in dental problems is leading to a higher volume of dental procedures.
• Oral Health & Cosmetic Awareness: Greater awareness regarding the importance of oral health and cosmetic dentistry is prompting more individuals to seek professional dental treatments.
• Economic & Infrastructure Improvements: Improved income levels and enhanced healthcare infrastructure in various regions are making dental care more accessible.
• Demographic Shifts: A growing elderly population is expected to drive increased demand for dental services.

Market Restraints & Challenges

• Practitioner Shortages: A shortage of dental practitioners may hinder market growth.
• Insurance Limitations: Limited insurance coverage for dental procedures serves as a potential challenge.
• Clinical Factors: Potential adverse effects and patient needle phobia are noted as restraints.

Segment Analysis

By Drug Type

• Articaine: This segment is expected to grow at the highest CAGR during the forecast period. Its rapid expansion is driven by several structural advantages over other anesthetics. Unlike other amide anesthetics that contain a benzene ring, articaine features a thiophene ring, which results in increased lipid solubility and improved penetration into tissues and nerve membranes. This enhanced diffusion through both hard and soft tissues makes articaine particularly effective for mandibular infiltrations, where nerve blocks are often required with other anesthetics. Dentists find articaine performs better in areas with dense bone structures. Furthermore, various studies have confirmed its safety profile for appropriate use among elderly and pediatric populations.

By Route of Administration

• Topical Anesthetics: This segment is projected to experience the highest growth in the dental anesthetics market. Growth is driven by widespread use in standard procedures, ease of application, non-invasiveness, and the ability to provide quick surface anesthesia. Adoption is further supported by new technologies such as gels, metered-dose sprays, and patches, as well as the introduction of needle-free anesthesia and various flavor options. While limited by a short duration of action, their reliability and broad applications continue to fuel growth.

By End User

• Dental Clinics: This segment is expected to dominate the dental anesthetics market during the forecast period. Demand is primarily driven by the expansion of dental clinics in developing regions of Latin America and Asia Pacific. As dental services become more accessible in countries such as Vietnam, Indonesia, and India, more patients are seeking surgeries requiring effective pain management. Key drivers for clinic expansion include rising middle-class incomes, urbanization, and increasing oral health awareness, leading to a higher need for topical and local anesthetics for restorative and cosmetic procedures.

Regional Analysis

Asia Pacific

• Market Outlook: The Asia Pacific region is expected to register the highest CAGR during the forecast period.
• Key Drivers: Growth is fueled by the rising prevalence of dental infections, greater oral health awareness, and a large, aging population that contributes to increased healthcare spending. Improvements in healthcare infrastructure, higher disposable incomes, and advancements in dental anesthetics technologies are also expected to drive the market.

Competitive Landscape

Supply-Side Participant Summary

• By Company Type:
• Tier 1: 35%
• Tier 2: 40%
• Tier 3: 25%
• By Designation:
• C-level Executives: 20%
• D-level Executives: 35%
• Others: 45%
• By Region:
• Asia Pacific: 28%
• North America: 25%
• Europe: 23%
• Latin America: 17%
• Middle East & Africa: 7%

Prominent Market Players

• Septodont Holding (France)
• DENTSPLY SIRONA (US)
• Pierrel (Italy)
• Huons Global (South Korea)
• Normon (Spain)
• DFL Indústria e Comércio S/A (Brazil)
• Ultradent Products Inc. (US)
• Hikma Pharmaceuticals Plc (UK)
• Clarben Laboratories (Spain)
• New Stetic S.A (Colombia)
• Primex Pharmaceuticals (Switzerland)
• Keystone Industries (US)
• Centrix, Inc. (US)
• GC SHOWAYAKUHIN CORPORATION (Japan)
• DMG America LLC (US)
• Zeyco (Mexico)
• Zymeth Pharmaceutical (India)
• Cetylite, Inc. (US)
• ICPA Health Products Limited (India)
• Crosstex International, Inc. (US)
• Young Innovations, Inc. (US)
• Mark3 (Cargus International, Inc.) (US)
• J.Morita Corp. (Japan)
• Kulzer GmbH (Germany)
• Integra Lifesciences Corporation (US)

Research Coverage & Value Proposition

Scope of Study

This research focuses on estimating market size and growth potential across drug type, route of administration, end user, and geographic region. It includes a comprehensive competitive analysis of key players, featuring observations on product offerings, recent developments, and market strategies.

Key Insights Provided

• Strategic Drivers & Opportunities: Analysis of increasing patient pools, demand for cosmetic procedures, and technological advancements. It also explores opportunities such as the rising number of Dental Service Organizations (DSOs), growing private equity investments, emerging markets, and dental tourism.
• Market Penetration: Comprehensive information on product portfolios offered by top global players.
• Product Enhancement/Innovation: Detailed insights into upcoming trends and product launches.
• Market Development: Analysis of profitable rising markets categorized by drug type, administration route, end user, and region.
• Market Diversification: Information regarding new products, growing geographies, and recent developments.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of leading players.

Reasons to Buy the Report

This report serves as a vital resource for market leaders and new entrants by providing approximate revenue figures for the overall market and its subsegments. It enables stakeholders to understand the competitive landscape to better position their businesses, develop go-to-market strategies, and gain insights into critical market drivers, restraints, challenges, and opportunities.

• 1 INTRODUCTION 23

  • 1.1 STUDY OBJECTIVES 23

  • 1.2 MARKET DEFINITION 23

  • 1.3 STUDY SCOPE 24

    • 1.3.1 MARKETS COVERED & REGIONAL SCOPE 24

    • 1.3.2 INCLUSIONS & EXCLUSIONS 25

    • 1.3.3 YEARS CONSIDERED 25

  • 1.4 CURRENCY CONSIDERED 26

  • 1.5 UNIT CONSIDERED 26

  • 1.6 STAKEHOLDERS 26

• 2 RESEARCH METHODOLOGY 27

  • 2.1 RESEARCH DATA 27

    • 2.1.1 SECONDARY DATA 28

      • 2.1.1.1 Key data from secondary sources 29

    • 2.1.2 PRIMARY DATA 30

      • 2.1.2.1 Key data from primary sources 31
      • 2.1.2.2 Key industry insights 32

  • 2.2 MARKET SIZE ESTIMATION 34

  • 2.3 MARKET BREAKDOWN & DATA TRIANGULATION 39

  • 2.4 MARKET SHARE ESTIMATION 41

  • 2.5 STUDY ASSUMPTIONS 41

  • 2.6 RESEARCH LIMITATIONS 41

    • 2.6.1 SCOPE-RELATED LIMITATIONS 41

    • 2.6.2 METHODOLOGY-RELATED LIMITATIONS 41

  • 2.7 RISK ASSESSMENT 42

• 3 EXECUTIVE SUMMARY 43

• 4 PREMIUM INSIGHTS 46

  • 4.1 DENTAL ANESTHETICS MARKET OVERVIEW 46

  • 4.2 ASIA PACIFIC: DENTAL ANESTHETICS MARKET, BY ROUTE OF ADMINISTRATION AND COUNTRY (2024) 47

  • 4.3 DENTAL ANESTHETICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 48

  • 4.4 DENTAL ANESTHETICS MARKET: REGIONAL MIX 48

  • 4.5 DENTAL ANESTHETICS MARKET: EMERGING ECONOMIES VS. DEVELOPED MARKETS 49

• 5 MARKET OVERVIEW 50

  • 5.1 INTRODUCTION 50

  • 5.2 MARKET DYNAMICS 51

    • 5.2.1 DRIVERS 51

      • 5.2.1.1 Increasing patient pool for dental treatments 51
        • 5.2.1.1.1 Dental caries and other dental disorders 51
        • 5.2.1.1.2 Geriatric population and edentulism 52
        • 5.2.1.1.3 Periodontal diseases 53
        • 5.2.1.1.4 Changing lifestyles and unhealthy food habits 54
      • 5.2.1.2 Increasing demand for advanced cosmetic dental procedures 54
      • 5.2.1.3 Technological advancements in anesthetic delivery 55

    • 5.2.2 RESTRAINTS 55

      • 5.2.2.1 Potential adverse effects 55

    • 5.2.3 OPPORTUNITIES 56

      • 5.2.3.1 Rising number of DSOs and growing private equity investments 56
      • 5.2.3.2 Emerging markets 58
      • 5.2.3.3 Growing dental tourism 58

    • 5.2.4 CHALLENGES 59

      • 5.2.4.1 Dearth of trained dental practitioners 59
      • 5.2.4.2 Needle phobia 59

  • 5.3 PORTER’S FIVE FORCES ANALYSIS 60

    • 5.3.1 INTENSITY OF COMPETITIVE RIVALRY 61

    • 5.3.2 BARGAINING POWER OF SUPPLIERS 61

    • 5.3.3 BARGAINING POWER OF BUYERS 61

    • 5.3.4 THREAT OF SUBSTITUTES 61

    • 5.3.5 THREAT OF NEW ENTRANTS 62

  • 5.4 REGULATORY ANALYSIS 62

    • 5.4.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 62

    • 5.4.2 REGULATORY LANDSCAPE 65

  • 5.5 INDUSTRY TRENDS 66

    • 5.5.1 METERED SPRAY SYSTEMS 66

    • 5.5.2 JET INJECTION SYSTEMS 66

  • 5.6 REIMBURSEMENT SCENARIO 66

  • 5.7 TECHNOLOGY ANALYSIS 67

    • 5.7.1 KEY TECHNOLOGIES 67

      • 5.7.1.1 Vasoconstrictors 67
      • 5.7.1.2 Buffering agents 67

    • 5.7.2 COMPLEMENTARY TECHNOLOGIES 68

      • 5.7.2.1 Computer-controlled local anesthetic delivery (CCLAD) systems 68

    • 5.7.3 ADJACENT TECHNOLOGIES 68

      • 5.7.3.1 Reversal agents 68

  • 5.8 KEY CONFERENCES & EVENTS, 2025-2026 69

  • 5.9 PRICING ANALYSIS 70

    • 5.9.1 AVERAGE SELLING PRICE TREND OF INJECTABLE ANESTHETICS, BY REGION 70

    • 5.9.2 INDICATIVE SELLING PRICE OF DENTAL ANESTHETICS, BY KEY PLAYER 70

  • 5.10 TRADE ANALYSIS 71

    • 5.10.1 IMPORT DATA FOR DENTAL ANESTHETICS (HS CODE: 300390), 2020-2024 72

    • 5.10.2 EXPORT DATA FOR DENTAL ANESTHETICS (HS CODE: 300390), 2020-2024 72

  • 5.11 PATENT ANALYSIS 73

    • 5.11.1 PATENT PUBLICATION TRENDS FOR DENTAL ANESTHETICS 73

    • 5.11.2 JURISDICTION ANALYSIS: TOP APPLICANTS FOR PATENTS IN DENTAL ANESTHETICS MARKET 73

  • 5.12 VALUE CHAIN ANALYSIS 76

  • 5.13 ECOSYSTEM ANALYSIS 77

  • 5.14 SUPPLY CHAIN ANALYSIS 78

  • 5.15 CASE STUDY ANALYSIS 80

    • 5.15.1 CASE STUDY 1: ORAQIX TOPICAL ANESTHETIC SIGNIFICANTLY REDUCED PAIN DURING SRP, ENHANCING COMFORT AND PATIENT ACCEPTANCE OF PERIODONTAL THERAPY 80

    • 5.15.2 CASE STUDY 2: PROCAINE HYDROCHLORIDE PROVIDES SAFE DENTAL ANESTHESIA FOR PATIENT WITH LIDOCAINE ALLERGIES AND SEVERE PHOBIA 80

    • 5.15.3 CASE STUDY 3: COMPUTERIZED ANESTHESIA SYSTEM AND PATIENT EDUCATION REDUCE DENTAL ANXIETY IN EXTRACTION PROCEDURES 81

  • 5.16 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 81

  • 5.17 KEY STAKEHOLDERS & BUYING CRITERIA 82

    • 5.17.1 KEY STAKEHOLDERS IN BUYING PROCESS 82

    • 5.17.2 BUYING CRITERIA 83

  • 5.18 ADJACENT MARKET ANALYSIS 84

  • 5.19 UNMET NEEDS/END-USER EXPECTATIONS 84

  • 5.20 IMPACT OF AI/GENERATIVE AI ON DENTAL ANESTHETICS MARKET 86

  • 5.21 IMPACT OF 2025 US TARIFF - OVERVIEW 86

    • 5.21.1 INTRODUCTION 86

    • 5.21.2 KEY TARIFF RATES 87

    • 5.21.3 PRICE IMPACT ANALYSIS 88

    • 5.21.4 IMPACT ON END-USER INDUSTRIES 88

• 6 DENTAL ANESTHETICS MARKET, BY DRUG TYPE 89

  • 6.1 INTRODUCTION 90

  • 6.2 LIDOCAINE 92

    • 6.2.1 RAPID ONSET AND VERSATILE FORMULATIONS TO DRIVE MARKET 92

  • 6.3 MEPIVACAINE 94

    • 6.3.1 UPTAKE IN PEDIATRIC & GERIATRIC POPULATIONS TO FUEL MARKET 94

  • 6.4 ARTICAINE 96

    • 6.4.1 IDEAL CHOICE FOR EXTENDED SURGICAL PROCEDURES TO PROPEL MARKET 96

  • 6.5 BUPIVACAINE 98

    • 6.5.1 PROVISION OF EFFECTIVE POST-OPERATIVE PAIN RELIEF TO SUPPORT MARKET GROWTH 98

  • 6.6 PRILOCAINE 100

    • 6.6.1 LOWER TOXICITY PROFILE TO FUEL UPTAKE 100

  • 6.7 OTHER DRUG TYPES 101

• 7 DENTAL ANESTHETICS MARKET, BY ROUTE OF ADMINISTRATION 103

  • 7.1 INTRODUCTION 104

  • 7.2 TOPICAL ANESTHETICS 106

    • 7.2.1 GROWING PATIENT PREFERENCE FOR NEEDLE-FREE ALTERNATIVES TO BOOST DEMAND 106

  • 7.3 INJECTABLE ANESTHETICS 108

    • 7.3.1 HIGH PRECISION AND EFFECTIVENESS TO PROPEL MARKET 108

  • 7.4 SYRINGES 110

    • 7.4.1 ADVANCEMENTS IN SYRINGE DESIGN TO FUEL MARKET 110

  • 7.5 NEEDLES 112

    • 7.5.1 RISING FOCUS ON INFECTION CONTROL AND PATIENT COMFORT TO SUPPORT MARKET GROWTH 112

• 8 DENTAL ANESTHETICS MARKET, BY END USER 114

  • 8.1 INTRODUCTION 115

  • 8.2 HOSPITALS 115

    • 8.2.1 ABILITY TO PURCHASE ADVANCED DENTISTRY EQUIPMENT TO DRIVE MARKET 115

  • 8.3 DENTAL CLINICS 117

    • 8.3.1 RISING DEMAND FOR COSMETIC & RESTORATIVE DENTAL PROCEDURES TO PROPEL MARKET 117

  • 8.4 OTHER END USERS 119

• 9 DENTAL ANESTHETICS MARKET, BY REGION 121

  • 9.1 INTRODUCTION 122

  • 9.2 EUROPE 124

    • 9.2.1 MACROECONOMIC OUTLOOK FOR EUROPE 124

    • 9.2.2 GERMANY 127

      • 9.2.2.1 Favorable government policies for reimbursement to expedite growth 127

    • 9.2.3 ITALY 130

      • 9.2.3.1 Rising adoption of digital dentistry techniques to augment growth 130

    • 9.2.4 SPAIN 132

      • 9.2.4.1 Presence of well-established dental healthcare infrastructure to foster growth 132

    • 9.2.5 FRANCE 134

      • 9.2.5.1 Favorable distribution network and reimbursement scenario to aid growth 134

    • 9.2.6 UK 136

      • 9.2.6.1 Booming geriatric population to stimulate growth 136

    • 9.2.7 REST OF EUROPE 138

  • 9.3 NORTH AMERICA 139

    • 9.3.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 140

    • 9.3.2 US 143

      • 9.3.2.1 High per capita income and quality of treatment to support growth 143

    • 9.3.3 CANADA 144

      • 9.3.3.1 Rising healthcare expenditure to sustain growth 144

  • 9.4 ASIA PACIFIC 146

    • 9.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 147

    • 9.4.2 SOUTH KOREA 150

      • 9.4.2.1 Growing elderly population to fuel market 150

    • 9.4.3 JAPAN 153

      • 9.4.3.1 Surge in age-related dental issues to promote growth 153

    • 9.4.4 CHINA 155

      • 9.4.4.1 Shift in demographic trend to accelerate growth 155

    • 9.4.5 INDIA 157

      • 9.4.5.1 Growing cosmetic dentistry sector to fuel market 157

    • 9.4.6 AUSTRALIA 159

      • 9.4.6.1 Increasing access to dental services to favor growth 159

    • 9.4.7 REST OF ASIA PACIFIC 160

  • 9.5 LATIN AMERICA 162

    • 9.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 162

    • 9.5.2 BRAZIL 164

      • 9.5.2.1 Booming dental tourism to contribute to growth 164

    • 9.5.3 ARGENTINA 166

      • 9.5.3.1 Growing focus on oral health to propel market 166

    • 9.5.4 MEXICO 168

      • 9.5.4.1 Affordable dental care costs to amplify growth 168

    • 9.5.5 REST OF LATIN AMERICA 170

  • 9.6 MIDDLE EAST & AFRICA 171

    • 9.6.1 GROWING FOCUS ON UNDERSERVED AREAS TO BOOST MARKET 171

    • 9.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 171

  • 9.7 GCC COUNTRIES 173

    • 9.7.1 INCREASING NUMBER OF PUBLIC CAMPAIGNS AND EDUCATION PROGRAMS TO DRIVE MARKET 173

    • 9.7.2 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES 173

• 10 COMPETITIVE LANDSCAPE 176

  • 10.1 INTRODUCTION 176

  • 10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 176

    • 10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN DENTAL ANESTHETICS MARKET 177

  • 10.3 MARKET SHARE ANALYSIS 178

  • 10.4 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 180

    • 10.4.1 STARS 180

    • 10.4.2 EMERGING LEADERS 180

    • 10.4.3 PERVASIVE PLAYERS 181

    • 10.4.4 PARTICIPANTS 181

    • 10.4.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 182

      • 10.4.5.1 Company footprint 182
      • 10.4.5.2 Region footprint 183
      • 10.4.5.3 Drug type footprint 184
      • 10.4.5.4 Route of administration footprint 185

  • 10.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 186

    • 10.5.1 PROGRESSIVE COMPANIES 186

    • 10.5.2 RESPONSIVE COMPANIES 186

    • 10.5.3 DYNAMIC COMPANIES 186

    • 10.5.4 STARTING BLOCKS 186

    • 10.5.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 188

      • 10.5.5.1 Detailed list of key startups/SMEs 188
      • 10.5.5.2 Competitive benchmarking of key startups/SMEs 188

  • 10.6 COMPANY VALUATION & FINANCIAL METRICS 189

    • 10.6.1 FINANCIAL METRICS 189

    • 10.6.2 COMPANY VALUATION 189

  • 10.7 BRAND/PRODUCT COMPARISON 190

  • 10.8 COMPETITIVE SCENARIO 191

    • 10.8.1 PRODUCT LAUNCHES 191

    • 10.8.2 DEALS 191

    • 10.8.3 EXPANSIONS 192

    • 10.8.4 OTHER DEVELOPMENTS 192

• 11 COMPANY PROFILES 193

  • 11.1 KEY PLAYERS 193

    • 11.1.1 SEPTODONT HOLDING 193

      • 11.1.1.1 Business overview 193
      • 11.1.1.2 Products/Services/Solutions offered 194
      • 11.1.1.3 Recent developments 195
        • 11.1.1.3.1 Product launches 195
        • 11.1.1.3.2 Deals 195
        • 11.1.1.3.3 Expansions 196
      • 11.1.1.4 MnM view 196
        • 11.1.1.4.1 Right to win 196
        • 11.1.1.4.2 Strategic choices 197
        • 11.1.1.4.3 Weaknesses & competitive threats 197

    • 11.1.2 DENTSPLY SIRONA 198

      • 11.1.2.1 Business overview 198
      • 11.1.2.2 Products/Services/Solutions offered 199
      • 11.1.2.3 Recent developments 200
        • 11.1.2.3.1 Deals 200
      • 11.1.2.4 MnM view 201
        • 11.1.2.4.1 Right to win 201
        • 11.1.2.4.2 Strategic choices 201
        • 11.1.2.4.3 Weaknesses & competitive threats 201

    • 11.1.3 PIERREL 202

      • 11.1.3.1 Business overview 202
      • 11.1.3.2 Products/Services/Solutions offered 202
      • 11.1.3.3 Recent developments 203
        • 11.1.3.3.1 Product launches 203
        • 11.1.3.3.2 Deals 203
      • 11.1.3.4 MnM view 204
        • 11.1.3.4.1 Right to win 204
        • 11.1.3.4.2 Strategic choices 204
        • 11.1.3.4.3 Weaknesses & competitive threats 204

    • 11.1.4 HUONS GLOBAL 205

      • 11.1.4.1 Business overview 205
      • 11.1.4.2 Products/Services/Solutions offered 206
      • 11.1.4.3 Recent developments 207
        • 11.1.4.3.1 Expansions 207
        • 11.1.4.3.2 Other developments 207
      • 11.1.4.4 MnM view 207
        • 11.1.4.4.1 Right to win 207
        • 11.1.4.4.2 Strategic choices 207
        • 11.1.4.4.3 Weaknesses & competitive threats 208

    • 11.1.5 NORMON 209

      • 11.1.5.1 Business overview 209
      • 11.1.5.2 Products/Services/Solutions offered 209
      • 11.1.5.3 MnM view 210
        • 11.1.5.3.1 Right to win 210
        • 11.1.5.3.2 Strategic choices 210
        • 11.1.5.3.3 Weaknesses & competitive threats 211

    • 11.1.6 DFL INDÚSTRIA E COMÉRCIO S/A 212

      • 11.1.6.1 Business overview 212
      • 11.1.6.2 Products/Services/Solutions offered 212

    • 11.1.7 ULTRADENT PRODUCTS INC 213

      • 11.1.7.1 Business overview 213
      • 11.1.7.2 Products/Services/Solutions offered 213
      • 11.1.7.3 Recent developments 214
        • 11.1.7.3.1 Deals 214
        • 11.1.7.3.2 Expansions 214
        • 11.1.7.3.3 Other developments 214

    • 11.1.8 PRIMEX PHARMACEUTICALS 215

      • 11.1.8.1 Business overview 215
      • 11.1.8.2 Products/Services/Solutions offered 215

    • 11.1.9 KEYSTONE INDUSTRIES 216

      • 11.1.9.1 Business overview 216
      • 11.1.9.2 Products/Services/Solutions offered 216

    • 11.1.10 CLARBEN LABORATORIES 217

      • 11.1.10.1 Business overview 217
      • 11.1.10.2 Products/Services/Solutions offered 218

    • 11.1.11 HIKMA PHARMACEUTICALS PLC 219

      • 11.1.11.1 Business overview 219
      • 11.1.11.2 Products/Services/Solutions offered 220

    • 11.1.12 ZEYCO 221

      • 11.1.12.1 Business overview 221
      • 11.1.12.2 Products/Services/Solutions offered 222

    • 11.1.13 NEW STETIC S.A 223

      • 11.1.13.1 Business overview 223
      • 11.1.13.2 Products/Services/Solutions offered 224

    • 11.1.14 CETYLITE, INC 225

      • 11.1.14.1 Business overview 225
      • 11.1.14.2 Products/Services/Solutions offered 225

    • 11.1.15 ICPA HEALTH PRODUCTS LIMITED 226

      • 11.1.15.1 Business overview 226
      • 11.1.15.2 Products/Services/Solutions offered 226

  • 11.2 OTHER PLAYERS 227

    • 11.2.1 CENTRIX, INC 227

    • 11.2.2 ZYMETH PHARMACEUTICAL 228

    • 11.2.3 DMG AMERICA LLC 229

    • 11.2.4 GC SHOWAYAKUHIN CORPORATION 230

    • 11.2.5 YOUNG INNOVATIONS, INC 231

    • 11.2.6 CROSSTEX INTERNATIONAL, INC 232

    • 11.2.7 MARK3 (CARGUS INTERNATIONAL, INC.) 233

    • 11.2.8 J. MORITA CORP 234

    • 11.2.9 KULZER GMBH 235

    • 11.2.10 INTEGRA LIFESCIENCES CORPORATION 236

• 12 APPENDIX 237

  • 12.1 DISCUSSION GUIDE 237

  • 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 241

  • 12.3 CUSTOMIZATION OPTIONS 243

  • 12.4 RELATED REPORTS 243

  • 12.5 AUTHOR DETAILS 244